Humacyte Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 184

Employees

  • Stock Symbol
  • HUMA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.45
  • (As of Friday Closing)

Humacyte General Information

Description

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2525 East Highway North Carolina 54
  • Durham, NC 27713
  • United States
+1 (919)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2525 East Highway North Carolina 54
  • Durham, NC 27713
  • United States
+1 (919)

Humacyte Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Humacyte Stock Performance

As of 20-Nov-2026, Humacyte’s stock price is $0.45. Its current market cap is $124M with 278M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.45 $0.54 $0.34 - $1.52 $124M 278M 5.42M -$0.45

Humacyte Financials Summary

As of 30-Sep-2026, Humacyte has a trailing 12-month revenue of $2.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 130,093 195,710 646,472 213,661
Revenue 2,396 2,038 0 0
EBITDA (79,441) (24,825) (136,338) (103,944)
Net Income (94,763) (40,833) (148,701) (110,776)
Total Assets 125,572 116,366 137,872 128,223
Total Debt 66,482 64,846 16,537 18,853
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Humacyte Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Humacyte‘s full profile, request access.

Request a free trial

Humacyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Humacyte‘s full profile, request access.

Request a free trial

Humacyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered hu
Biotechnology
Durham, NC
184 As of 2025

Madison, WI
 

Mississauga, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Humacyte Competitors (51)

One of Humacyte’s 51 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Sernova Biotherapeutics Corporation Mississauga, Canada
Orgenesis Corporation Germantown, MD
Orbsen Therapeutics Formerly PE-Backed Galway, Ireland
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 51 competitors. Get the full list »

Humacyte Patents

Humacyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024207955-A1 Devices and methods of a medicament-producing implantable matrix Pending 11-Jan-2023
EP-4648748-A2 Devices and methods of a medicament-producing implantable matrix Pending 11-Jan-2023
US-20260216406-A1 Devices and methods of a medicament-producing implantable matrix Pending 11-Jan-2023
WO-2024151852-A2 Devices and methods of a medicament-producing implantable matrix Inactive 11-Jan-2023
WO-2024151852-A3 Devices and methods of a medicament-producing implantable matrix Inactive 11-Jan-2023 A61K9/0024
To view Humacyte’s complete patent history, request access »

Humacyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Humacyte Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Humacyte‘s full profile, request access.

Request a free trial

Humacyte Acquisitions (2)

Humacyte’s most recent deal was a Merger/Acquisition with Alpha Healthcare Acquisition. The deal was made on 26-Aug-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alpha Healthcare Acquisition 26-Aug-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Biopharma Excellence 01-Jun-2021 Merger/Acquisition Other Pharmaceuticals and Biotechnology
To view Humacyte’s complete acquisitions history, request access »

Humacyte ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.74 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Humacyte’s complete esg history, request access »

Humacyte Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Biopharma Excellence Friedrichsdorf, Germany 2013

Humacyte FAQs

  • When was Humacyte founded?

    Humacyte was founded in 2004.

  • Where is Humacyte headquartered?

    Humacyte is headquartered in Durham, NC.

  • What is the size of Humacyte?

    Humacyte has 184 total employees.

  • What industry is Humacyte in?

    Humacyte’s primary industry is Biotechnology.

  • Is Humacyte a private or public company?

    Humacyte is a Public company.

  • What is Humacyte’s stock symbol?

    The ticker symbol for Humacyte is HUMA.

  • What is the current stock price of Humacyte?

    As of 20-Nov-2026 the stock price of Humacyte is $0.45.

  • What is the current market cap of Humacyte?

    The current market capitalization of Humacyte is $124M.

  • What is Humacyte’s current revenue?

    The trailing twelve month revenue for Humacyte is $2.4M.

  • Who are Humacyte’s competitors?

    Centrose, Sernova Biotherapeutics, Orgenesis, Orbsen Therapeutics, and Sangamo Therapeutics are some of the 51 competitors of Humacyte.

  • What is Humacyte’s annual earnings per share (EPS)?

    Humacyte’s EPS for 12 months was -$0.45.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process